Montrusco Bolton Investments Inc. grew its position in shares of Johnson & Johnson (NYSE:JNJ) by 47.6% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 69,860 shares of the company’s stock after acquiring an additional 22,527 shares during the quarter. Montrusco Bolton Investments Inc.’s holdings in Johnson & Johnson were worth $9,082,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in JNJ. Vanguard Group Inc. lifted its holdings in Johnson & Johnson by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock valued at $26,517,661,000 after purchasing an additional 3,023,110 shares during the last quarter. BlackRock Inc. lifted its holdings in Johnson & Johnson by 2.6% during the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock valued at $23,028,219,000 after purchasing an additional 4,332,612 shares during the last quarter. State Street Corp lifted its holdings in Johnson & Johnson by 4.3% during the 1st quarter. State Street Corp now owns 160,223,321 shares of the company’s stock valued at $19,955,806,000 after purchasing an additional 6,656,371 shares during the last quarter. FMR LLC lifted its holdings in Johnson & Johnson by 5.9% during the 2nd quarter. FMR LLC now owns 27,237,648 shares of the company’s stock valued at $3,603,268,000 after purchasing an additional 1,509,745 shares during the last quarter. Finally, Capital World Investors lifted its holdings in Johnson & Johnson by 4.1% during the 2nd quarter. Capital World Investors now owns 26,510,007 shares of the company’s stock valued at $3,507,009,000 after purchasing an additional 1,050,000 shares during the last quarter. 65.70% of the stock is owned by institutional investors.
Shares of Johnson & Johnson (NYSE:JNJ) traded up $0.97 during midday trading on Friday, hitting $145.76. The company had a trading volume of 5,450,000 shares, compared to its average volume of 5,920,000. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a 52 week low of $110.76 and a 52 week high of $146.42. The company has a market capitalization of $391,590.00, a PE ratio of 25.31, a P/E/G ratio of 2.73 and a beta of 0.80.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, topping the Zacks’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The company had revenue of $19.65 billion for the quarter, compared to analysts’ expectations of $19.29 billion. During the same quarter last year, the business earned $1.68 earnings per share. Johnson & Johnson’s revenue was up 10.3% on a year-over-year basis. research analysts anticipate that Johnson & Johnson will post 7.28 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.31%. The ex-dividend date is Monday, February 26th. Johnson & Johnson’s payout ratio is currently 58.33%.
JNJ has been the subject of several research reports. Cowen reaffirmed an “outperform” rating and set a $155.00 price target (up previously from $147.00) on shares of Johnson & Johnson in a report on Wednesday, October 18th. Jefferies Group raised their price target on Johnson & Johnson from $157.00 to $160.00 and gave the company a “buy” rating in a report on Monday, October 16th. Zacks Investment Research raised Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Wednesday, October 4th. Credit Suisse Group set a $154.00 price objective on Johnson & Johnson and gave the stock an “outperform” rating in a research report on Thursday, October 19th. Finally, Barclays increased their price objective on Johnson & Johnson from $140.00 to $148.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 18th. Four analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $145.94.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.